Clinical Trials
11 trialsNCT05987956 2026-05-22
Drugs-SNPs
Medicine Invention Design, Inc
Phase 2/3 Active not recruiting
NCT05096663 2026-05-18
Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
SWOG Cancer Research Network
Phase 2/3 Active not recruiting
NCT03637816 2026-04-15
Anamorelin Hydrochloride in Reducing Anorexia in Patients With Advanced Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 2/3 Active not recruiting
NCT03178552 2026-03-09
B-FAST
Hoffmann-La Roche
Phase 2/3 Active not recruiting
NCT06984588 2026-01-30
A Study to Compare Uliledlimab Combined With Toripalimab, Toripalimab Monotherapy, and Pembrolizumab Monotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1- and CD73- Selected Non-Small Cell Lung Cancer
TJ Biopharma Co., Ltd.
Phase 2/3 Active not recruiting
NCT05785767 2026-01-22
A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)
Regeneron Pharmaceuticals
Phase 2/3 Active not recruiting
NCT05800015 2026-01-22
A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer
Regeneron Pharmaceuticals
Phase 2/3 Active not recruiting
NCT05020769 2025-09-26
SI-B001 Combined With Osimertinib Mesylate Tablets in the Treatment of Recurrent Metastatic Non-small Cell Lung Cancer.
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2/3 Active not recruiting
NCT07145333 2025-09-08
Drug-SNP
Medicine Invention Design, Inc
Phase 2/3 Active not recruiting
NCT01064466 2025-07-24
Drugs-SNPs
Medicine Invention Design, Inc
Phase 2/3 Active not recruiting
NCT07076693 2025-07-22
Standard-of-care Systemic Therapy With or Without Local Therapy in Patients With Oligoprogressive Non-Small Cell Lung Cancer(NSCLC）
Shanghai Chest Hospital
Phase 2/3 Active not recruiting